8-K: Akebia Therapeutics Reports Mixed 2023 Results, Awaits Key FDA Decision on Vadadustat

Akebia Therapeutics announced its fourth quarter and full year 2023 financial results, highlighted by Auryxia revenue within guidance and preparations for a potential vadadustat launch, pending FDA approval.

Summary

• Akebia Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2023.
• The company is awaiting a potential U.S. approval for vadadustat, with a PDUFA date of March 27, 2024.
• Akebia's 2023 Auryxia net product revenue was $170.3 million, within the guidance range of $170.0 $175.0 million.
• The company secured a $55.0 million term loan facility with BlackRock and raised $26.0 million from an at-the-market (ATM) offering.
• Total revenue for 2023 was $194.6 million, compared to $292.5 million in 2022.
• Net product revenue for 2023 was $170.3 million, compared to $176.9 million in 2022.
• The company reported a net loss of $51.9 million for the full year 2023, compared to a net loss of $94.2 million in 2022.
• Cash and cash equivalents were approximately $42.9 million as of December 31, 2023.
• Akebia believes its current resources are sufficient to fund operations for at least 24 months if vadadustat is approved.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the upcoming PDUFA date for vadadustat and the strengthened financial position, but tempered by the decrease in overall revenue and the net loss for the year. The company is clearly focused on the potential approval of vadadustat.

Positives

• Auryxia net product revenue for 2023 was within the company's guidance.
• The company secured a significant term loan facility with BlackRock, strengthening its financial position.
• Akebia successfully raised additional capital through an ATM offering.
• The company has introduced new pipeline programs, expanding its potential future product offerings.
• The net loss for 2023 improved compared to 2022.
• The company believes it has sufficient cash to fund operations for at least 24 months if vadadustat is approved.
• The BlackRock loan provides an extended interest-only period if vadadustat is approved by June 30, 2024.

Negatives

• Total revenue for 2023 decreased compared to 2022.
• Net product revenue for 2023 decreased compared to 2022.
• License, collaboration and other revenues decreased significantly in 2023 compared to 2022.
• The company reported a net loss for the full year 2023, although it was an improvement from 2022.
• Cash and cash equivalents decreased from $90.5 million in 2022 to $42.9 million in 2023.

Risks

• The potential for a negative decision by the FDA regarding vadadustat could impact the company's cash runway.
• The company faces competition for Auryxia, including potential generic entrants.
• There are risks associated with the manufacturing, supply chain, and quality of products.
• The company's future performance is dependent on the successful launch and market acceptance of vadadustat.
• The company's ability to attract and retain qualified personnel is a risk factor.
• The company's financial position is dependent on the approval of vadadustat.

Future Outlook

Akebia expects Auryxia net product revenue growth in 2024 with a similar quarterly cadence to 2023 and believes its current resources are sufficient to fund operations for at least 24 months if vadadustat is approved. The company will continue to carefully manage expenses while investing in a potential vadadustat launch.

Management Comments

• We are eagerly awaiting the PDUFA date for vadadustat, now within weeks, and we believe the progress we have made over the past 12 months has positioned our team to successfully launch vadadustat in the U.S., if approved, said John P. Butler, Chief Executive Officer of Akebia.
• A U.S. approval for vadadustat will be transformational for Akebia and a significant step toward our goal of bettering the lives of people impacted by kidney disease.
• We are approaching a potential U.S. launch of vadadustat from an extremely strong financial position.
• We expect Auryxia net product revenue growth in 2024, with a quarterly revenue cadence that is similar to 2023, we executed a term loan with BlackRock and implemented other financial strategies that together we believe will support our business operations for at least two years if vadadustat is approved.
• As we move forward, we will continue to carefully manage expenses, while investing appropriately for a successful potential launch of vadadustat, Mr. Butler added.

Industry Context

The announcement comes as the biopharmaceutical industry focuses on developing treatments for chronic kidney disease and related conditions. The potential approval of vadadustat is a significant event for Akebia and the broader renal therapeutics market, as it would provide a new oral treatment option for anemia due to chronic kidney disease.

Comparison to Industry Standards

• Akebia's Auryxia revenue of $170.3 million is comparable to other companies in the renal space with similar products, such as Keryx Biopharmaceuticals (acquired by Akebia) which had peak sales of around $100 million for Auryxia.
• The company's focus on vadadustat aligns with the industry trend of developing oral HIF-PH inhibitors for anemia, competing with companies like FibroGen and GSK, which have similar products in the market or in development.
• The $55 million debt financing from BlackRock is a common strategy for biotech companies to fund late-stage development and commercialization, similar to other companies that have secured debt financing from institutional investors.
• The company's cash position of $42.9 million is relatively low compared to larger pharmaceutical companies, but is typical for a company of its size and stage of development.

Management Changes

Stakeholder Impact

• Shareholders are impacted by the financial results and the potential approval of vadadustat.
• Employees are impacted by the company's financial stability and future prospects.
• Patients with chronic kidney disease could benefit from the potential approval of vadadustat.
• Creditors are impacted by the company's debt financing and repayment obligations.

Next Steps

• Akebia is preparing for a potential launch of vadadustat, pending FDA approval.
• The company will continue to manage expenses while investing in the potential vadadustat launch.
• Akebia will monitor the PDUFA date of March 27, 2024, for the FDA decision on vadadustat.

Key Dates

Keywords

vadadustat, Auryxia, chronic kidney disease, anemia, FDA, PDUFA, biopharmaceutical, renal, BlackRock, financing, revenue, net loss